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Methods: 
Obesity and type 2 diabetes mellitus (T2DM) are associated with poorer cognitive per-
formance. Reports suggest that bariatric surgery may lead to improvements in cognitive 
processes. However, the potential eff ects of mood improvements have not yet been 
evaluated. The aim of the study was to assess the eff ects of intragastric balloon (IGB) 
induced weight loss on cognitive performance in morbidly obese patients and relate 
them to changes in mood. 
Twenty four morbidly obese patients (43.9±12.0 years of age, 145.6±22.3kg, body mass 
index (BMI): 49.8±6.9, 11 females, 14 with T2DM), underwent tests of visual short-term 
memory (Benton Visual Retention Test), sustained and divided attention (Color Trail 
Test), and verbal short-term memory: (Digit Span from WAIS-R) 1) a month before IGB 
insertion, 2) three months after, 3) one month after IGB removal. Depressive symptoms 
were evaluated with the Beck Depression Inventory (BDI).
Signifi cant cognitive improvement was observed over the fi rst three months of IGB 
treatment in verbal short-term memory, visual short-term memory, and sustained and 
divided attention among all patients, regardless of their T2DM status. However, these 
changes correlated with weight loss only in patients without comorbid T2DM. The cogni-
tive changes were not associated with changes in depressive symptoms. The improved 
cognitive performance was sustained over the last three months of the treatment. 
Results:
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INTRODUCTION
A growing body of research demonstrates that 
obesity is associated with poorer cognitive pro-
cesses in healthy adults [14], faster cognitive de-
cline in the elderly [36], poorer executive functions 
at any age [4,11,12,28,30,31].  Compared to non-
obese individuals, obese individuals demonstrate 
lowered performance in attention switching skills, 
inhibition, fl exibility and attention [8,35].  Finally, 
it was demonstrated that a larger increase in BMI 
in adulthood was associated with lower executive 
function [31].  A series of studies focused on the 
speed of cognitive aging among overweight and 
obese in twin populations demonstrated that be-
ing overweight or obese in midlife and late midlife 
was associated with lower cognitive skills  in later 
life [5,15]. Moreover, it appears that people suff er-
ing from obesity are often more prone to experi-
ence distress, depression and eating disorders, 
such as Binge Eating Disorder, among others 
[17,33].
A review article by Brandao et al. [3] revealed 
that 20%–56% of preoperative bariatric patients 
have a current psychiatric diagnosis. Moreover, 
the authors pointed out that major depressive 
disorder is the most frequent condition, followed 
by social phobia, anxiety disorders, somatization, 
hypochondria, and obsessive-compulsive disor-
der [3]. Higher BMI [21,34] and increased visceral 
fat [25]  are frequently reported to be associated 
with depressive symptoms, e.g., in adults with cur-
rent depression, or a history of diagnosed depres-
sion or anxiety [34]. Obese people are not only at 
a higher risk of depression but depression is also a 
predictor of weight gain and future obesity [2,23]. 
Consistently, an epidemiological study of almost 
44,800 (United States) nationally representative 
respondents [16] demonstrated that obese wom-
en and overweight (but not obese) men were 
more prone to depressive mood than their non-
overweight counterparts; the depressive mood 
was operationalized by whether or not the partici-
pant reported feeling sad, blue, or depressed for 
more than seven days during the month prior to 
answering the questionnaire.
T2DM not only exacerbates these cognitive def-
icits, but also detrimentally aff ects the following 
cognitive domains: abstract reasoning, memory 
with subdomains of working memory, immedi-
ate memory and learning rate, and incidental 
memory, information processing speed, attention 
and executive function, and visuospatial skills [37]. 
Furthermore, morbid conditions co-occurring 
with obesity, such as T2DM, may be related to de-
clines in episodic memory [27], working, and ver-
bal memory, as well as mental fl exibility [19].
Bariatric surgery is the only eff ective method 
leading to sustained long-term weight loss and 
reversal of medical dysfunction associated with 
obesity. One explanation shows that obesity and 
depression can be related through infl ammation 
[26,32]. Previous neuroimaging studies suggested 
that bariatric surgery leads to changes in pat-
terns of brain activity elicited by appetitive stimuli 
[29], improvements in memory function over just 
three months following the surgery [13], and im-
provements in attention, executive function, and 
memory [1]. However, performance on tests of 
language functioning remained stable[1]. We have 
demonstrated that three-month-long treatment 
with an intragastric balloon (IGB) leads to remis-
sion of neuroinfl ammation in patients with T2DM 
participating in this study [10].
IGB placement is an endoscopic method of obe-
sity treatment. It is a minimally invasive procedure 
inducing weight loss by reducing the gastric reser-
voir capacity, leading to premature satiation and 
prolonged satiety, and modulation of hormone 
levels regulating energy balance. The balloon is a 
smooth, spherical, saline or air-fi lled, silicone elas-
tomer of the size between 500 and 800 ml. There 
is one type of balloon adjustable in size. Balloon 
treatment is temporary and the balloon should 
be removed after six months, except for adjust-
able balloon, which can remain in the stomach for 
12 months. This method is used for patients who 
1) need a surgery, but whose excessive weight 
would put them risk or reduces their likelihood 
of good outcome, 2) patients who refuse bariatric 
surgery or would benefi t from a “bridge” to bariat-
Morbid obesity treatment with an intragastric balloon leads to cognitive improvements. 
These improvements are not associated with mood changes. 
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30-63 — indicates severe depression. All tests were 
performed by an experienced (MJ) in a quiet room, 
same every time. All procedures were performed 
according to manuals, in the morning hours, one 
on one with the psychologist; no third party ob-
servers were present. Among OD, scores of four pa-
tients indicated mild depression and scores of four 
patients indicated moderate depression, whereas 
among OB two patients were qualifi ed as having 
mild depression and one as having moderate de-
pression. No patient obtained scores qualifying 
as having severe depression. None of the patients 
reported a diagnosis of major depressive disorder, 
nor was taking anti-depressive medications at the 
time of the study.
All enrolled patients were consecutive patients 
qualifi ed for IGB treatment over two years, who 
did not have counterindications for magnetic 
resonance.
Among OD patients, 11 reported hypertension, 
ten were taking hypertension medications. How-
ever, when their blood pressure was measured, 
they all met the criteria for hypertension. Seven 
patients had dyslipidemia (fi ve taking medica-
tions), 10 had a fatty liver diagnosis, four were 
cigarette smokers; smoking is a factor known to 
detrimentally aff ect cognitive function [7]. Nine of 
them had a history of gastritis, seven were H. Py-
lori positive, two patients had cholecystolithiasis, 
two were after cholecystectomy because of chol-
ecystolithiasis, two had diabetic polyneuropathy, 
one had diabetic retinopathy, three had obstruc-
tive sleep apnea (OSA). Twelve OD were taking 
metformin and three of them were taking other 
oral anti-diabetic medications. Three OD were 
taking insulin. Due to IGB treatment, two of them 
ceased taking insulin, another two reduced the 
number of types of anti-diabetic medication. Five 
OD had normal blood pressure after IGB removal. 
One patient had gastric ulcer hemorrhage caused 
by taking aspirin against medical prescription. It 
led to premature IGB removal one month prior to 
the scheduled time [24]. However, his scores on 
ric surgery (weight loss preceding the actual sur-
gery), and 3) patients with a BMI of up to 35 with 
or without comorbidities, who have not achieved 
sustained weight loss with other methods.
Here, we evaluated if IGB treatment lasting for 
six month leads to improvements in short-term 
memory, processing speed, visual search and 
visual memory, and whether these changes are 
related to changes in depressive symptomatology 
and weight changes.
METHODS
This study was part of a larger project involving 
neuroimaging using magnetic resonance methods 
to evaluate neural changes accompanying weight 
loss [10]. Fourteen morbidly obese patients with co-
morbid T2DM (hence labeled OD patients, 47.9±7.8 
years of age, fi ve females, 144±28kg, BMI=47.2±6.6, 
%EW=89±27% — excess body weight) and 10 mor-
bidly obese patients without T2DM (hence labeled 
OB patients, 48.6±14.9 years of age, six females, 
148±13kg, BMI=53.4±5.9, percent excess body 
weight, EW=114±24%)  underwent pen and paper 
versions of tests of visual short-term memory (Ben-
ton Visual Retention Test, 37), visual search and sus-
tained and divided attention (Color Trail Test, CTT-1, 
CTT-2, Polish normalization, [6], auditory atten-
tion and verbal working memory (Digit Span from 
WAIS-R, Polish version revised and renormalized 
in 2004), and depressive symptoms (Polish transla-
tion of Beck Depression Inventory, BDI, [22]: a) one 
month before IGB insertion, b) three months after, 
c) one month after IBG removal (fi g. 1). They were 
consecutive patients qualifi ed for saline-fi lled IGB 
treatment lasting six months between April 2015 
and December 2016, who did not have contraindi-
cations for magnetic resonance. Parallel versions of 
these tests were utilized in random order. Depres-
sive symptoms were evaluated at all time-points. 
The standard cut-off  scores are as follows: 0-9 — in-
dicates no depression; 10–18 — indicates mild de-
pression; 19-29 — indicates moderate depression; 
Fig. 1.  Timeline of the study. Patients undergo the 1st cognitive testing four weeks before IGB insertion, 2nd testing three 
months after, and the last, 3rd testing four weeks after IGB removal. 
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tions between changes in cognitive and BDI scores 
were calculated using Pearson’s product-moment 
correlation. A signifi cance level of p<0.05 was con-
sidered statistically signifi cant. Given the prelimi-
nary nature of the study, no corrections for multiple 
comparisons were performed. All statistical tests 
were conducted with R version 3.4.4 (with the “ez” 
package developed for that version of R).
RESULTS
Weight changes induced by IGB between 
insertion and three months thereafter 
The 2 (group) x 3 (time-point) repeated meas-
ures analyses yielded signifi cant main eff ects 
of treatment for body weight [F(2,44)=57.45, 
p<0.001], and BMI [F(2,44)=60.90, p<0.001]. The 
main group eff ect was signifi cant only for BMI 
[F(1,22)=6.43, p=0.02].  None of the interactions 
reached statistical signifi cance. These eff ects in 
OD correspond to 10.6% and 5.1% decrease in 
BMI over the fi rst three months of therapy and 
the following three months of therapy, whereas 
the corresponding BMI decreases in OB are 8.6% 
and 5.1%. In terms of body weight, it decreased by 
10.6% and 5.4% respectively in OD, and 8.3% and 
4.6%, respectively in OB.
Cognitive changes between IGB insertion 
and three months thereafter
The 2 (group) x 2 (time-point) repeated meas-
ures analyses yielded signifi cant main eff ects of 
treatment for digit span [F(1,22)=4.66, p=0.042], 
completion time for CTT-1 [F(1,22)=4.41, p=0.048], 
completion time for CTT-2 [F(1,22)=4.68, p=0.042], 
and number of errors regarding colors in CTT-2 
[F(1,22)=)=8.08, p=0.009]. These eff ects corre-
sponded to a 9% increase in repeated digits in 
the tests were within the range of results obtained 
by other patients taking part in the study; his ex-
clusion did not aff ect the results.
Among OB patients, two reported hypertension 
and were taking hypertension medications. Two 
patients had dyslipidemia (all of them were taking 
medications), one had a fatty liver diagnosis, and one 
was cigarette smoker. Four of them had a history of 
gastritis, two were H. Pylori positive, one patient had 
cholecystolithiasis, two were after cholecystectomy 
because of cholecystolithiasis, and one had hypo-
thyroidism. All the patients were Caucasian.
All participants gave written informed con-
sent to all procedures approved by the Bioethical 
Commission at the Military Institute of Aviation 
Medicine, Warsaw, Poland (permission number 
03/2013, in agreement with the Declaration of 
Helsinki. Written informed consent was obtained 
from all participants in this study.
Statistical analyses
The changes in body weight and BMI were 
evaluated using 2 (groups: OD vs. OB) x 3 (time-
points) repeated measures ANOVA. The group ef-
fect (T2DM diagnosis) is referred to as the T2DM 
eff ect, whereas the time eff ect is referred to as the 
eff ect of treatment for excessive body weight.
Given the non-linearity changes in cognitive 
and BDI scores (tab. 1), they were evaluated us-
ing 2 (groups: OD vs. OB) x 2 (time-points) ANOVA 
repeated measures, separately for the fi rst three 
months of the treatment (fi g. 1), and for the follow-
ing three months. In the analyses, time-point was 
used as the intra-group factor, whereas the T2DM 
status was used as the between-group factor. The 
interactions between the time-point and the T2DM 
status were the basis for evaluation of diff erences in 
cognitive recovery between both groups. Correla-
TP1 TP2 TP3
Digit span 12.4 ± 4.1 13.6 ± 4.7 14.2 ± 4.5
CTT-1 time 43.5 ± 10.5 38.8 ± 10.5 40.5 ± 12.3
CTT-2 time 87.3 ± 22.6 80.8 ± 22.6 78.4 ± 20.3
CTT-2 #colors 0.4 ± 0.5 0.0 ± 0.2 0.2 ± 0.4
BENTON #errors 4.2 ± 2.2 3.0 ± 2.8 3.5 ± 2.7
BDI 10.3 ± 6.8 10.2 ± 9.0 6.0 ± 6.3
OD: BMI [kg/m2] 47.2 ± 6.6 42.2 ± 7.3 39.8 ±7.6
OD: Body mass [kg] 144.0 ± 27.6 128.7 ± 25.7 120.9 ±25.6
OB: BMI [kg/m2] 53.4 ± 5.9 48.8 ± 4.6 46.1 ± 4.4
OB: Body mass [kg] 147.9 ± 12.8 135.6 ± 12.7 128.2 ± 14.8
Tab. 1.  Mean scores obtained at respective time points. CTT-1 time and CTT-2 time – the time needed to fi nish the 
respective tests. CTT-2 #colors - properly selected digit but wrong color. OD: BMI, OD: Body mass – mean BMI 
and mean body mass in patients with type 2 diabetes mellitus; OB: BMI, OB: Body mass – mean BMI and mean 
body mass in patients without T2DM.
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fect between T2DM diagnosis and cognitive im-
provement due to treatment. This is unexpected 
given that our magnetic resonance spectroscopy 
study in the same population demonstrated nor-
malization of brain myo-inositol, a marker of neu-
roinfl ammation, only in the OD group during the 
treatment [10]. Similarly, T2DM was associated 
with more brain atrophy in the OD than in OB [9] 
and IGB treatment lead to some morphological 
brain recovery in the OD cohort (to be described 
separately). However, the cognitive improve-
ments correlated with decreases in body weight 
and BMI only in the group of patients without 
T2DM; it suggests that the mechanisms of cogni-
tive improvement in patients with and without 
comorbid T2DM might be diff erent. Cognitive 
improvements after IGB insertion were not re-
lated to changes in depressive symptomatology. 
Similar fi ndings, i.e. a lack of relationship between 
history of major depressive disorder preceding 
bariatric surgery with post-surgery cognitive im-
provements, were reported [1].
The lack of statistically signifi cant changes over 
the last three months of treatment may be due to 
smaller weight loss over this period than over the 
fi rst three months of treatment (tab. 1) . It may also 
be interpreted that the observed cognitive im-
provements are transient, possibly associated with 
the eff ects of IGB on the host [20]. Therefore, the 
changes in cognition due to IGB treatment should 
be also evaluated long-term after IGB removal.
The major limitations of this study are the small 
sample size and the small/limited battery used in 
the assessment. Future studies should utilize com-
prehensive cognitive batteries and larger cohorts. 
To sum up, similarly to more invasive bariatric 
techniques, morbid obesity treatment with the 
intragastric balloon leads to cognitive improve-
ments that are related to weight loss in patients 
without comorbid type 2 diabetes mellitus. These 
improvements do not seem to be related or ac-
companied by signifi cant mood changes.
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the Digit Span test, an 8% decrease in CTT-2, as 
well as a 89% decrease in the number of errors re-
garding colors, as well as a 40% decrease in the 
total number of errors in the Benton test (tab. 1). 
Furthermore, there was an impact of treatment 
on the total number of errors in the Benton test 
[F(1,22)= 6.30, p=0.020]. Neither the main eff ect 
of T2DM status nor the interaction between the 
T2DM status and the treatment were signifi cant 
for any measure. No signifi cant main eff ects or 
interactions were found for the BDI scores. The 
mean results for each measure at each time point 
are provided in table 1.
Cognitive changes between three months 
after insertion and one month after IGB 
removal
No change in cognitive measures was signifi -
cant between three months after IGB insertion 
and one month after its removal. Neither T2DB 
nor the interaction between T2DM status and 
time was signifi cant for any measure. Similarly, for 
the BDI scores, none of the eff ects was signifi cant. 
Correlates of cognitive changes
In OD, none of the absolute changes in cogni-
tive measures between one month before inser-
tion and three months thereafter correlated with 
changes in BDI, body mass, and BMI. 
However, in OB, larger weight loss and larger 
BMI loss correlated with a larger reduction in num-
ber of errors regarding color on CTT-2 (r < -0.641, 
p < 0.046), as well as larger weight loss and larger 
BMI loss had a correlation to improvement in digit 
span (r < -0.604, p=0.06).
DISCUSSION
We have observed improvements in short-term 
memory, visual search and memory and sustained 
and divided attention in morbidly obese patients 
during intragastric balloon treatment over the fi rst 
three months of the treatment, regardless of de-
pressive state changes (measured using the Beck 
Depression Inventory) and type 2 diabetes mel-
litus diagnosis. Interestingly, cognitive improve-
ments correlated with decreases in body weight 
and BMI only in the group of patients without 
T2DM. However, no statistically signifi cant chang-
es were observed over the following three months 
of treatment.
These fi ndings in general support the exist-
ing body of evidence that bariatric surgery leads 
to improvement in cognitive functioning [1,13]. 
Surprisingly, we did not fi nd any interaction ef-
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